Start-up of a 5-year European project that seeks to tackle the challenge of developing a type of oral medicine that can pass through the digestive tract intact.
If successful, the TRANS-INT consortium will contribute to improving the treatment of chronic diseases, such as diabetes, and pain.
The researcher Ernest Giralt, an expert in the design of peptides and proteins with the capacity to cross biological barriers, forms part of a macro-consortium that involves 17 institutions in Europe.
Iproteos is developing a drug to treat the symptoms of schizophrenia and has already obtained its first results in animals.
The company has completed a first funding round, achieving more than 100,000 euros, and anticipates a second round of funding from business angels this autumn.
Set up in 2011 as a biotech spin-off from the Institute for Research in Biomedicine and the University of Barcelona, Iproteos has received support from the Ministry of Enterprise and Labour through the Evaluation Units managed by ACC1Ó.
The newspaper “El Periódico de Catalunya” devotes a page to a project between IRB Barcelona and the VHIO. This project seeks to develop a new strategy against brain tumours; this approach is based on the use of peptide shuttle that can cross the blood-brain barrier to reach the tumour. Ernest Giralt and Meritxell Teixidó are the IRB...
The media echo the resolution of the “Prova’t” call launched by the Government of Catalonia. IRB Barcelona takes part in this call with a collaborative project on brain cancer with the Vall d’Hebron Institute of Oncology (VHIO).
A collaborative project run by the Institute for Research in Biomedicine (IRB Barcelona) and Vall d’Hebron Institute of Oncology (VHIO) has received one of the funding concessions of the first call of the “Prova’t” programme, promoted by the “Generalitat de Catalunya” (Autonomous Government of Catalonia). “Prova’t” seeks to boost the transfer of results from research centres in Catalonia to the productive sector.
The project will develop a new therapeutic strategy for glioblastoma, a very aggressive type of brain cancer with poor prognosis. This research involves the work of scientists Meritxell Teixidó and Ernest Giralt, at IRB Barcelona, and Joan Seoane at VHIO.
Spain’s Ministry of Sciences gives the award in recognition of his
contributions to the design, synthesis, controlled modification and
structure of peptides and proteins.
Iproteos has been a semi-finalist in the II Award for the Best Entrepreneurial Biotechnology Project, a technology transfer prize given by the Spanish Society of Biochemistry (Sociedad Española de Bioquímica (SEBBM)). The spin-off, which is promoted by IRB Barcelona –located at the Barcelona Science Park- and the University of Barcelona –through the Bosch y Gimpera Foundation, also at the Park – was founded in June with the mission to develop and commercialize a new generation of more efficient low cost drugs with fewer side effects.
Read the new
Read the new
Read the new